Public
Private
Find an authorized treatment center by location:
Beijing
Shanghai
Shenzhen
Tianjin
Hangzhou
Wuhan
Beijing GoBroad Boren Hospital
Beijing
Beijing Lu Dao Pei Hospital
Beijing
Peking University Institute of Hematology, Peking University People's Hospital
Visit Website
Beijing
Department of Hematology, Beijing Chao-yang Hospital, Capital Medical University
Beijing
Shanghai Tongji Hospital of Tongji University
Visit Website
Shanghai
Jiahui International Cancer Center
Shanghai
GoBroad Medical Institute of Hematology (Shanghai Center)
Shanghai
The University of Hong Kong-Shenzhen Hospital
Visit Website
Shenzhen
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Visit Website
Tianjin
The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU)
Visit Website
Hangzhou
Introduction of Union Hospital, Tongji Medical College,Huazhong University of Science and Technology
Visit Website
Wuhan
Most Recommended Top Treatment Centers
Peking University Institute of Hematology, Peking University People's Hospital
location:Beijing, China
Learn More >
Department of Hematology, Beijing Chao-yang Hospital, Capital Medical University
location:Beijing, China
Learn More >
Shanghai Tongji Hospital of Tongji University
location:Shanghai, China
Learn More >
The University of Hong Kong-Shenzhen Hospital
location:Shenzhen, China
Learn More >
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
location:Tianjin, China
Learn More >
The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU)
location:Hangzhou, China
Learn More >
Most Recommended Top Treatment Centers
Beijing GoBroad Boren Hospital
location:Beijing, China
Learn More >
Beijing Lu Dao Pei Hospital
location:Beijing, China
Learn More >
Jiahui International Cancer Center
location:Shanghai, China
Learn More >
GoBroad Medical Institute of Hematology (Shanghai Center)
location:Shanghai, China
Learn More >
Fucaso® (Equecabtagene Autoleucel Injection)

-- The World's First Approved Fully Human CAR-T Therapy

Breakthrough fully human CAR structure
  • Full epitope of light and heavy chains binds tightly to BCMA
  • Fast dissociation, low exhaustion
  • Low immunogenicity
Durable persistence
  • Median duration of persistence time 419 days
  • 12-month sustained MRD negativity rate 81.7%
  • 12-month PFS rate 85.5%
Strong efficacy
  • ORR 98.9%
  • ≥CR rate 82.4%
  • MRD negativity rate 97.8%
Returning to life upon single-dose treatment
Excellent safety
  • No ≥ Grade 3 ICANS
  • Incidence of ≥ Grade 3
  • No movement/cognitive disorder observed No Parkinson's disease found